<DOC>
	<DOCNO>NCT02282254</DOCNO>
	<brief_summary>Closed-loop strategy compose three component : glucose sensor read glucose level , insulin pump infuse insulin dose mathematical algorithm decide required insulin dosage base sensor 's reading . A dual-hormone closed-loop strategy would regulate glucose level infusion two hormone : insulin glucagon . The main objective project compare efficacy single-hormone dual-hormone closed-loop strategy regulate overnight glucose level in-patient study type 1 diabetes adult hypoglycemia unawareness document nocturnal hypoglycemia . The investigator hypothesize dual-hormone closed-loop strategy effective regulating overnight glucose level compare single-hormone closed-loop strategy .</brief_summary>
	<brief_title>Closed-loop Control Overnight Glucose Levels ( Artificial Pancreas ) Type 1 Diabètes Adults With Hypoglycemia Unawareness Documented Nocturnal Hypoglycemia</brief_title>
	<detailed_description>Closed-loop strategy compose three component : glucose sensor read glucose level , insulin pump infuse insulin dose mathematical algorithm decide required insulin dosage base sensor 's reading . A dual-hormone closed-loop strategy would regulate glucose level infusion two hormone : insulin glucagon . The investigator aim conduct 1st randomize cross-over trial compare single- hormone dual-hormone closed-loop strategy regulate overnight glucose level . The investigator aim compare two intervention 10 hour two subgroup adult type 1 diabètes . Patients subgroups present document nocturnal hypoglycemia . One subgroup consist patient hypoglycemia unawareness subgroup consist patient hypoglycemia unawareness . This study allow determine great benefit closed-loop strategy higher-risk hypoglycemia unaware group .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 1</mesh_term>
	<mesh_term>Hypoglycemia</mesh_term>
	<mesh_term>Unconsciousness</mesh_term>
	<mesh_term>Hormones</mesh_term>
	<mesh_term>Glucagon</mesh_term>
	<criteria>1 . Males females ≥ 18 year old . 2 . Clinical diagnosis type 1 diabetes least one year . 3 . The subject insulin pump therapy least 3 month . 4 . HbA1c ≤ 12 % . 5 . Hypoglycemia awareness unawareness assess questionnaire . 6 . Documented NH runin period . 1 . Clinically significant nephropathy , neuropathy retinopathy judge investigator . 2 . Recent ( &lt; 6 month ) acute macrovascular event e.g . acute coronary syndrome cardiac surgery . 3 . Pregnancy . 4 . Severe hypoglycemic episode within two week screen . 5 . Current use glucocorticoid medication ( except low stable dose ) . 6 . Known suspect allergy trial product snack content . 7 . Other serious medical illness likely interfere study participation ability complete trial judgment investigator . 8 . Anticipating significant change exercise regimen admission ( i.e . start stop organize sport ) . 9 . Failure comply team 's recommendation ( e.g . willing eat snack , willing change pump parameter , etc ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>Type 1 diabetes</keyword>
	<keyword>Hypoglycemia unawareness</keyword>
	<keyword>Nocturnal hypoglycemia</keyword>
	<keyword>Closed-loop strategy</keyword>
	<keyword>Artificial pancreas</keyword>
	<keyword>Glucagon</keyword>
	<keyword>Hypoglycemia</keyword>
	<keyword>Insulin</keyword>
</DOC>